July 17 (Reuters) - GSK will halt development of an experimental drug to treat refractory chronic cough after it failed to meet key goals across two late-stage trials, sending the British drugmaker's ...

Mixed Phase 3 data for camlipixant prompted the British pharma to cease development, making the drug the third from its class to fail.

Chronic cough, with symptoms lasting more than eight weeks, affects approximately one in 10 adults. Cough is among the most common reasons for seeking medical care in the United States, yet chronic ...

About 4% to 10% of the adult population experiences chronic cough — a cough lasting eight weeks or more, or at least four weeks for children. A chronic cough doesn't call for immediate medical ...

Some gut health issues manifest as completely unrelated symptoms. Dr Salhab shares what chronic cough may indicate and ways to manage it.

When a cough refuses to subside despite treatment, it is worth asking a more important question—not what medicine will ...

Initiated Phase 3 OCEAN-1 trial for patients with idiopathic pulmonary fibrosis-related chronic cough in the second quarter; Phase 3 OCEAN-2 ...

For adults with a history of depression, chronic cough can increase the risk of recurrent depressive events, a study found. Adults with chronic cough experience a disproportionate burden of depressive ...

Chronic cough is a condition that lasts for 8 weeks or longer in adults or 4 weeks or longer in children, and there are now updated guidelines for the diagnosis and management of cough, even though ...

Chronic cough took center stage at the European Respiratory Society (ERS) Congress session titled "Conditions We Are Just Dealing With the Tip of the Iceberg in Primary Care: Frequently Mismanaged ...

The most common presenting complaints included shortness of breath, rhinorrhea, and hoarseness. Nearly half of patients presenting with chronic cough responded favorably to treatment with oral ...